[Translation] A Phase I study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of APS03118 in adult patients with unresectable, locally advanced or metastatic solid tumors harboring a RET mutation or fusion
主要目的:
确定APS03118的最大耐受剂量(MTD)和/或II期推荐剂量(RP2D)
评价APS03118的安全性和耐受性 次要目的:
评价APS03118的药代动力学(PK)特征
根据第1.1版实体瘤疗效评价标准(RECIST)评估APS03118的初步抗肿瘤疗效
[Translation] main purpose:
Determination of maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of APS03118
To evaluate the safety and tolerability of APS03118 Secondary Objectives:
Evaluation of the pharmacokinetic (PK) profile of APS03118
The preliminary antitumor efficacy of APS03118 was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1